No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Guggenheim Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Cuts Target Price to $10
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $11
Compass Therapeutics Is Maintained at Buy by Guggenheim
Stifel Nicolaus Sticks to Its Buy Rating for Compass Therapeutics (CMPX)
Express News | Compass Therapeutics Inc. : Guggenheim Cuts Target Price to $10 From $12
Analysts Are Bullish on These Healthcare Stocks: Compass Therapeutics (CMPX), REPRO-MED Systems (KRMD)